MCID: TTN003
MIFTS: 61

Tetanus malady

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Tetanus

Aliases & Descriptions for Tetanus:

Name: Tetanus 12 50 56 52 41 3 3 42 14 69
Lockjaw 50 3
Infection Due to Clostridium Tetani 12
Clostridial Tetanus 12

Characteristics:

Orphanet epidemiological data:

56
tetanus
Prevalence: <1/1000000 (France),<1/1000000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:11338
ICD10 33 A35
ICD9CM 35 037
MeSH 42 D013742
NCIt 47 C85185
Orphanet 56 ORPHA3299
UMLS via Orphanet 70 C0039614
ICD10 via Orphanet 34 A33 A34 A35
MESH via Orphanet 43 D013742
UMLS 69 C0039614

Summaries for Tetanus

MedlinePlus : 41 tetanus is a serious illness caused by clostridium bacteria. the bacteria live in soil, saliva, dust, and manure. the bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. the infection causes painful tightening of the muscles, usually all over the body. it can lead to "locking" of the jaw. this makes it impossible to open your mouth or swallow. tetanus is a medical emergency. you need to get treatment in a hospital. a vaccine can prevent tetanus. it is given as a part of routine childhood immunization. adults should get a tetanus shot, or booster, every 10 years. if you get a bad cut or burn, see your doctor - you may need a booster. immediate and proper wound care can prevent tetanus infection.

MalaCards based summary : Tetanus, also known as lockjaw, is related to hepatitis and rabies, and has symptoms including fever and pruritus. An important gene associated with Tetanus is VAMP7 (Vesicle Associated Membrane Protein 7), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Iron and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, heart and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

CDC : 3 Tetanus is an infection caused by bacteria called Clostridium tetani. When the bacteria invade the body, they produce a poison (toxin) that causes painful muscle contractions. Another name for tetanus is “lockjaw”. It often causes a person’s neck and jaw muscles to lock, making it hard to open the mouth or swallow. CDC recommends vaccines for infants, children, teens, and adults to prevent tetanus.

Disease Ontology : 12 A primary bacterial infectious disease that results_in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

Wikipedia : 71 Tetanus, also known as lockjaw, is an infection characterized by muscle spasms. In the most common type,... more...

Related Diseases for Tetanus

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.9 IFNG IL10 IL2
2 rabies 29.9 CD40LG CD79A
3 lymphoblastic leukemia 29.7 IL13 IL4 IL5
4 inflammatory breast carcinoma 29.5 CD79A IL10 LTA
5 rheumatoid arthritis 28.7 CD40LG CD79A IFNG IL10 IL2 IL2RA
6 tetanus neonatorum 12.4
7 diphtheria 11.4
8 immunodeficiency 25 10.8
9 pertussis 10.6
10 influenza 10.4
11 myoglobinuria recurrent 10.4 IFNG IL4
12 haemophilus influenzae 10.4
13 kaposiform hemangioendothelioma 10.3 IL2 LTA
14 autosomal dominant deafness-onychodystrophy syndrome 10.3 IFNG IL2 IL4
15 alcoholic neuropathy 10.3 CD40LG CD79A
16 camptodactyly vertebral fusion 10.3 CD40LG CD79A
17 maturity-onset diabetes of the young 10.3 CD40LG IL10
18 tungiasis 10.3 IFNG IL10 IL4
19 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 IL4
20 chronic thromboembolic pulmonary hypertension 10.3 IFNG IL10 IL2
21 neurotic disorder 10.3 IFNG IL10 IL4
22 microcephaly 10.3 IFNG IL10 IL2
23 ectodermal dysplasia bartalos type 10.3 IFNG IL10 IL4
24 spinal polio 10.3 CD40LG CD79A
25 conduct disorder 10.3 CD40LG IFNG IL10
26 pancreatic signet ring cell adenocarcinoma 10.3 CD40LG IFNG IL10
27 carrion's disease 10.3 NSF SNAP25 VAMP2
28 unilateral retinoblastoma 10.3 CD40LG CD79A
29 hepatitis b 10.3
30 hereditary alpha tryptasemia syndrome 10.3 CD40LG IFNG IL10
31 mesangial proliferative glomerulonephritis 10.3 CD40LG CD79A
32 vestibule of mouth cancer 10.3 IL10 IL4 LTA
33 venezuelan hemorrhagic fever 10.3 CD79A IFNG IL2
34 plummer's disease 10.3 CD40LG IFNG IL10
35 congenital hypothyroidism 10.3 CD40LG IL10 IL4
36 urethral intrinsic sphincter deficiency 10.3 IFNG IL4 IL5
37 hemangioma of orbit 10.3 CD40LG CD79A IL2
38 crustacean allergy 10.3 IFNG IL13 IL4
39 israeli tick typhus 10.3 CD40LG IFNG IL13
40 multiple mitochondrial dysfunctions syndrome 10.3 IFNG IL10 IL5
41 delta chain disease 10.3 CD40LG CD79A
42 immune-complex glomerulonephritis 10.3 CD79A IFNG IL4
43 myofibroma 10.3 IFNG IL10 IL13
44 gonadal disease 10.3 CD79A IL2 IL4
45 eye carcinoma in situ 10.3 IFNG IL2 IL4
46 alkhurma hemorrhagic fever 10.3 CD40LG CD79A IL4
47 polyneuropathy due to drug 10.3 CD40LG CD79A IL4
48 cutaneous ganglioneuroma 10.3 CD40LG CD79A IL4
49 hypoparathyroidism, x-linked 10.3 CD40LG CD79A IL4
50 abdominal tuberculosis 10.3 CD40LG CD79A IL10

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus

Symptoms & Phenotypes for Tetanus

UMLS symptoms related to Tetanus:


fever, pruritus

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.19 CCR7 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.19 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.19 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.19 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.19 VAMP7 CCR7 IL10 IL13
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.19 IL13
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.19 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.19 VAMP7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.19 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.19 VAMP7
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.19 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.19 CCR7
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.19 CCR7 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.19 IL13
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.19 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.19 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.19 CCR7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.19 VAMP7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.19 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.19 VAMP7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.19 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.19 VAMP7
23 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.19 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.19 VAMP7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.19 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.19 VAMP7
27 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.19 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.19 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.19 IL10
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.13 IL2RA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.13 IL2RA
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.13 NSF IL10
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.13 NSF VAMP7 IL10 IL2RA
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.13 IL2RA
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.13 VAMP7
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.13 VAMP7
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.13 IL2RA
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.13 NSF
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.13 IL2RA IL10
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.13 IL10
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.13 IL10
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.13 IL10
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.13 NSF
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 STX3 CD40LG IL10 IL2 IL2RA LTA
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 STX3 CD27 CD40LG IL10 IL2 IL2RA

MGI Mouse Phenotypes related to Tetanus:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 SNAP25 VAMP3 VAMP7 CCR7 CD40LG CD79A
2 hematopoietic system MP:0005397 10.3 LTA VAMP2 VAMP3 CCR7 CD27 CD40LG
3 immune system MP:0005387 10.25 CCR7 CD27 CD40LG CD79A IFNG IL10
4 endocrine/exocrine gland MP:0005379 10.22 CCR7 CD40LG IFNG IL10 IL13 IL2
5 mortality/aging MP:0010768 10.13 CD40LG IFNG IL10 IL13 IL2 IL2RA
6 digestive/alimentary MP:0005381 10.1 CCR7 IFNG IL10 IL13 IL2 IL2RA
7 nervous system MP:0003631 10 CCR7 CD40LG CD79A IFNG IL10 IL4
8 liver/biliary system MP:0005370 9.97 CD79A IFNG IL10 IL2 IL4 IL5
9 no phenotypic analysis MP:0003012 9.81 IL2 IL4 SNAP23 SNAP25 IFNG IL10
10 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL2 IL2RA IL4
11 vision/eye MP:0005391 9.23 IL2RA IL4 LTA SNAP25 CCR7 IFNG

Drugs & Therapeutics for Tetanus

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
2
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
3
Remifentanil Approved Phase 4 132875-61-7 60815
4
Natalizumab Approved, Investigational Phase 4 189261-10-7
5
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
6
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
7
rituximab Approved Phase 4,Phase 2 174722-31-7 10201696
8
Adalimumab Approved Phase 4 331731-18-1 16219006
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Desflurane Approved Phase 4 57041-67-5 42113
11
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
12
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
15
Daclizumab Approved, Investigational Phase 4,Phase 2 152923-56-3
16
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
17
Ibuprofen Approved Phase 4 15687-27-1 3672
18
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
19
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
20
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
21
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
22
Lopinavir Approved Phase 4 192725-17-0 92727
23
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
24
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 54575, 6560146 143
27 tannic acid Approved, Nutraceutical Phase 4
28 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
30 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
31 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
32 Antacids Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antirheumatic Agents Phase 4,Phase 1,Phase 2
38 Antidotes Phase 4,Phase 3,Phase 2
39 Calcium, Dietary Phase 4,Phase 3,Phase 2
40 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 4,Phase 2
42 Antimetabolites, Antineoplastic Phase 4,Phase 2
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Vitamin B Complex Phase 4,Phase 2
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
46 Analgesics, Opioid Phase 4
47 Anesthetics Phase 4,Phase 1
48 Anesthetics, General Phase 4
49 Anesthetics, Intravenous Phase 4
50 Central Nervous System Depressants Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 584)
id Name Status NCT ID Phase
1 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
2 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Pneumococcal Vaccines Early and in Combination Unknown status NCT01174849 Phase 4
6 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
7 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4
8 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
9 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
10 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
11 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
12 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
13 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
14 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
15 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
16 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
17 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
18 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
19 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
20 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
21 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
22 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
23 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
24 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
25 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
26 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
27 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
28 Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision Completed NCT02884310 Phase 4
29 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
30 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
31 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
32 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
33 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
34 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
35 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
36 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
37 Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA) Completed NCT00111410 Phase 4
38 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4
39 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
40 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination Completed NCT00548171 Phase 4
41 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
42 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
43 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
44 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
45 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
46 A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) Completed NCT01163747 Phase 4
47 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
48 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
49 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Completed NCT01362322 Phase 4
50 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: tetanus

Genetic Tests for Tetanus

Anatomical Context for Tetanus

MalaCards organs/tissues related to Tetanus:

39
Spinal Cord, Heart, Brain, Bone, Skeletal Muscle, T Cells, Testes

Publications for Tetanus

Articles related to Tetanus:

(show top 50) (show all 1033)
id Title Authors Year
1
Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. ( 28081971 )
2017
2
Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. ( 28081174 )
2017
3
Augmentation of humoral and cellular immunity in response to Tetanus and Diphtheria toxoids by supercritical carbon dioxide extracts of Hippophae rhamnoides L. leaves. ( 28092864 )
2017
4
Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid. ( 27927058 )
2017
5
Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States. ( 26899377 )
2016
6
Generalized tetanus could be complicated with Guillain-BarrAc syndrome. ( 27109107 )
2016
7
Performance of a bedside test for tetanus immunity: results of a cross-sectional study among three EDs in the Netherlands in 2012-2013. ( 27609502 )
2016
8
Synthetic Cannabinoid-Induced Immunosuppression Augments Cerebellar Dysfunction in Tetanus-Toxin Treated Mice. ( 27871157 )
2016
9
Does vaccination ensure protection? Assessing diphtheria and tetanus antibody levels in a population of healthy children: A cross-sectional study. ( 27930568 )
2016
10
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. ( 26803328 )
2016
11
Current epidemiology of tetanus in England, 2001-2014. ( 27535200 )
2016
12
Fragment C Domain of Tetanus Toxin Mitigates Methamphetamine Neurotoxicity and Its Motor Consequences in Mice. ( 26945022 )
2016
13
Tetanus disease and deaths in men reveal need for vaccination. ( 27516639 )
2016
14
Booster vaccination against tetanus and diphtheria: insufficient protection against diphtheria in young and elderly adults. ( 27602049 )
2016
15
Neuroprotective Effect of Non-viral Gene Therapy Treatment Based on Tetanus Toxin C-fragment in a Severe Mouse Model of Spinal Muscular Atrophy. ( 27605908 )
2016
16
A case of tetanus secondary to an odontogenic infection. ( 27927258 )
2016
17
A toe that pointed the wrong way: An unusual presentation of tetanus. ( 26933367 )
2016
18
Sex-differential effects on mortality of BCG and diphtheria-tetanus-pertussis vaccines in a rural area with high vaccination coverage: observational study from Senegal. ( 27738283 )
2016
19
Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons. ( 27498860 )
2016
20
Comparisons of the effect of naturally acquired maternal pertussis antibodies and antenatal vaccination induced maternal tetanus antibodies on infant's antibody secreting lymphocyte responses and circulating plasma antibody levels. ( 27176823 )
2016
21
Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-acellular Pertussis Vaccine in Mice. ( 28011915 )
2016
22
Tetanus neurotoxin HCC protein commits T cells to IFN-I^ producing cells. ( 27064869 )
2016
23
Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents. ( 27152501 )
2016
24
Undervaccination with diphtheria, tetanus, and pertussis vaccine: National trends and association with pertussis risk in young children. ( 27858500 )
2016
25
Tetanus, diphtheria, and acellular pertussis vaccination among women of childbearing age-United States, 2013. ( 27372388 )
2016
26
Successful elimination of maternal and neonatal tetanus in India: Ray of hope for other nations. ( 27904622 )
2016
27
Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine. ( 27038131 )
2016
28
Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis. ( 27060790 )
2016
29
Tetanus in New Zealand children: Intensive care management of a vaccine preventable disease. ( 27612025 )
2016
30
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. ( 27171114 )
2016
31
Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM. ( 27593883 )
2016
32
Effect of Tetanus-diphtheria Vaccine on Immune Response to Hepatitis B Vaccine in Low-responder Individuals. ( 27563430 )
2016
33
Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats. ( 27090294 )
2016
34
Immune Thrombocytopenia Following Diphtheria Pertussis- Tetanus and Oral Polio Vaccine. ( 27771689 )
2016
35
Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015. ( 27013434 )
2016
36
Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Co-Administered with Routine Childhood Vaccines in European Infants: An Open, Randomized Trial. ( 28002359 )
2016
37
Employers' Views on Influenza and Tetanus-Diphtheria-Pertussis Vaccination in the Workplace. ( 27058495 )
2016
38
Case fatality of adult tetanus in Africa: Systematic review and meta-analysis. ( 27538652 )
2016
39
The safety and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) booster vaccine in healthy Vietnamese children. ( 27435387 )
2016
40
Effect of introduction of pentavalent vaccine as replacement for Diphtheria-Tetanus-Pertussis and Hepatitis B vaccines on vaccination uptake in a health facility in Nigeria. ( 27108191 )
2016
41
Rapid assessment of tetanus vaccine-induced immunity in Bangladesh and the Gambia. ( 27916543 )
2016
42
Tetanus vaccination is associated with differential DNA-methylation: Reduces the risk of asthma in adolescence. ( 27866770 )
2016
43
Tetanus Immunity Gaps in Children 5-14 Years and Men a8Y 15 Years of Age Revealed by Integrated Disease Serosurveillance in Kenya, Tanzania, and Mozambique. ( 27920395 )
2016
44
Evaluation of tetanus antibody levels in adults in Yozgat, Turkey. ( 27513229 )
2016
45
Neonatal tetanus associated with skin infection. ( 27601113 )
2016
46
Erratum to: Clinical profile of tetanus patients attended at Felege Hiwot Referral Hospital, Northwest Ethiopia: a retrospective cross sectional study. ( 27516923 )
2016
47
Tetanus toxoid-loaded cationic non-aggregated nanostructured lipid particles triggered strong humoral and cellular immune responses. ( 27056086 )
2016
48
Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display Library. ( 27626445 )
2016
49
Prevention of Tetanus Outbreak Following Natural Disaster in Indonesia: Lessons Learned from Previous Disasters. ( 26960530 )
2016
50
Tetanus and Occam's Razor: Almost Forgotten but Not Gone: A Case Report. ( 27940761 )
2016

Variations for Tetanus

Expression for Tetanus

Search GEO for disease gene expression data for Tetanus.

Pathways for Tetanus

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show all 50)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CD27 CD40LG CD79A IFNG IL10 IL13
2
Show member pathways
13.87 CCR7 CD27 CD40LG IL10 IL13 IL2
3
Show member pathways
13.71 CCR7 CD27 CD40LG IFNG IL10 IL13
4
Show member pathways
13.47 CCR7 CD27 CD40LG IL10 IL13 IL2
5
Show member pathways
13.39 CD27 CD40LG IFNG IL10 IL13 IL2
6
Show member pathways
13.35 CCR7 CD27 CD40LG IL10 IL13 IL2
7
Show member pathways
12.9 CD40LG IFNG IL10 IL13 IL2 IL2RA
8
Show member pathways
12.83 IFNG IL13 IL2 IL2RA IL4 LTA
9
Show member pathways
12.71 CD40LG CD79A IFNG IL10 IL2 IL2RA
10
Show member pathways
12.67 IFNG IL10 IL13 IL2 IL2RA IL4
11 12.6 CD40LG CD79A IFNG IL10 IL2 IL2RA
12
Show member pathways
12.51 CD40LG IFNG IL10 IL2 IL4 IL5
13
Show member pathways
12.48 NSF SNAP23 SNAP25 VAMP2 VAMP7
14
Show member pathways
12.33 IFNG IL13 IL4 IL5
15
Show member pathways
12.26 CD40LG IFNG IL10 IL4
16
Show member pathways
12.26 IFNG IL10 IL13 IL2 IL2RA IL4
17 12.2 IL10 IL13 SNAP25 VAMP2
18
Show member pathways
12.16 IFNG IL10 IL13 IL2 IL4 IL5
19
Show member pathways
12.06 IL13 IL2 IL2RA IL5
20
Show member pathways
12.03 NSF SNAP25 STX3 VAMP2
21
Show member pathways
12.01 IFNG IL2 IL2RA IL4
22
Show member pathways
12.01 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
23
Show member pathways
11.98 IFNG IL10 IL2 LTA
24 11.93 CCR7 CD79A IFNG IL10 IL2 IL2RA
25 11.88 IFNG IL13 IL2 IL4 IL5
26
Show member pathways
11.81 CD27 CD40LG LTA
27
Show member pathways
11.81 CD40LG IFNG IL2 IL2RA IL4 IL5
28
Show member pathways
11.77 IL2 IL2RA IL4 LTA
29 11.77 IFNG IL10 IL2 IL2RA
30 11.76 IFNG IL10 IL2
31 11.76 CD40LG IL10 IL2RA IL4 IL5 LTA
32 11.74 CD40LG IL10 IL4 IL5 LTA
33 11.67 IL13 IL4 IL5
34
Show member pathways
11.67 CD40LG IFNG IL2
35
Show member pathways
11.65 IFNG IL2 IL2RA
36 11.59 CD27 CD40LG IL10
37 11.55 IL10 IL13 IL4
38 11.54 CD40LG IFNG IL10
39
Show member pathways
11.52 IFNG IL10 IL2 IL2RA
40 11.46 IFNG IL10 IL13 IL2 IL2RA IL4
41
Show member pathways
11.44 NSF SNAP25 VAMP2
42 11.4 IFNG IL13 IL4 IL5
43 11.37 IFNG IL10 IL13 IL2 IL2RA IL4
44 11.36 CD40LG IFNG IL2 IL2RA IL4 IL5
45 11.32 IFNG IL13 IL2 IL2RA
46 11.28 IFNG IL10 IL13 IL2 IL4 IL5
47 11.27 CD40LG IL10 IL13 IL2 IL4 IL5
48 10.99 IL13 IL4 IL5
49 10.65 SNAP25 VAMP2
50 10.58 IFNG IL10 IL13 IL2 IL4 IL5

GO Terms for Tetanus

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.92 SNAP23 SNAP25 VAMP2 VAMP3 VAMP7
2 cell surface GO:0009986 9.85 CCR7 CD27 CD40LG IL2RA VAMP3 VAMP7
3 neuron projection GO:0043005 9.7 IFNG SNAP23 SNAP25 STX3 VAMP2 VAMP3
4 phagocytic vesicle membrane GO:0030670 9.69 SNAP23 VAMP3 VAMP7
5 synaptic vesicle GO:0008021 9.62 SNAP25 STX3 VAMP2 VAMP7
6 clathrin-coated vesicle membrane GO:0030665 9.61 VAMP2 VAMP3 VAMP7
7 specific granule GO:0042581 9.57 SNAP23 STX3
8 azurophil granule GO:0042582 9.56 SNAP23 STX3
9 secretory granule GO:0030141 9.56 STX3 VAMP2 VAMP3 VAMP7
10 external side of plasma membrane GO:0009897 9.56 CCR7 CD27 CD40LG CD79A IFNG IL13
11 intracellular organelle GO:0043229 9.55 VAMP2 VAMP3
12 zymogen granule membrane GO:0042589 9.54 STX3 VAMP2
13 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.4 SNAP25 VAMP2
14 SNARE complex GO:0031201 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
15 plasma membrane GO:0005886 10.29 CCR7 CD27 CD40LG CD79A IL2RA LTA
16 intracellular GO:0005622 10.1 CCR7 CD27 CD40LG IL2 IL2RA IL5
17 extracellular space GO:0005615 10.06 CD40LG IFNG IL10 IL13 IL2 IL4

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.97 CCR7 CD27 IL10 IL13 LTA
2 response to ethanol GO:0045471 9.94 CD27 IL13 IL2 IL4
3 negative regulation of inflammatory response GO:0050728 9.88 IL10 IL2 IL2RA
4 inflammatory response GO:0006954 9.87 CCR7 CD27 CD40LG IL10 IL13 IL2RA
5 B cell differentiation GO:0030183 9.86 CD40LG CD79A IL10 IL4
6 positive regulation of cell adhesion GO:0045785 9.85 CCR7 IFNG STX3
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL2 IL4
8 vesicle fusion GO:0006906 9.84 STX3 VAMP2 VAMP3 VAMP7
9 exocytosis GO:0006887 9.83 NSF STX3 VAMP2 VAMP3 VAMP7
10 B cell proliferation GO:0042100 9.82 CD40LG CD79A IL10
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.8 IL10 IL13 IL4
12 positive regulation of activated T cell proliferation GO:0042104 9.79 IL2 IL2RA IL4
13 Golgi to plasma membrane protein transport GO:0043001 9.79 VAMP2 VAMP3 VAMP7
14 long-term synaptic potentiation GO:0060291 9.78 MPP2 SNAP25 STX3 VAMP2
15 positive regulation of interleukin-12 production GO:0032735 9.77 CCR7 CD40LG IFNG
16 defense response to protozoan GO:0042832 9.77 IFNG IL10 IL4
17 post-Golgi vesicle-mediated transport GO:0006892 9.76 SNAP23 VAMP2 VAMP7
18 negative regulation of growth of symbiont in host GO:0044130 9.74 IFNG IL10 LTA
19 calcium ion regulated exocytosis GO:0017156 9.72 VAMP2 VAMP3 VAMP7
20 negative regulation of nitric oxide biosynthetic process GO:0045019 9.71 IL10 IL4
21 positive regulation of macrophage activation GO:0043032 9.71 IL10 IL13
22 membrane fusion GO:0061025 9.71 SNAP23 STX3 VAMP2 VAMP3
23 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IFNG IL4
24 positive regulation of mast cell degranulation GO:0043306 9.7 IL13 IL4
25 positive regulation of immunoglobulin secretion GO:0051024 9.7 IL2 IL5 VAMP3
26 synaptic vesicle priming GO:0016082 9.69 SNAP23 SNAP25
27 synaptic vesicle docking GO:0016081 9.69 SNAP25 STX3
28 positive regulation of immunoglobulin production GO:0002639 9.69 IL13 IL4
29 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.69 SNAP23 SNAP25 STX3
30 SNARE complex assembly GO:0035493 9.68 VAMP3 VAMP7
31 negative regulation of lymphocyte proliferation GO:0050672 9.68 IL2 IL2RA
32 type 2 immune response GO:0042092 9.68 IL10 IL4
33 natural killer cell degranulation GO:0043320 9.68 VAMP2 VAMP7
34 mucus secretion GO:0070254 9.67 VAMP2 VAMP3
35 positive regulation of isotype switching to IgG isotypes GO:0048304 9.67 IFNG IL2 IL4
36 positive regulation of B cell proliferation GO:0030890 9.67 IL13 IL2 IL4 IL5
37 regulation of isotype switching GO:0045191 9.66 IL10 IL4
38 regulation of proton transport GO:0010155 9.66 IL13 IL4
39 negative regulation of T-helper 17 cell differentiation GO:2000320 9.65 IL2 IL4
40 eosinophil degranulation GO:0043308 9.65 VAMP2 VAMP7
41 regulation of T cell homeostatic proliferation GO:0046013 9.64 IL2 IL2RA
42 negative regulation of complement-dependent cytotoxicity GO:1903660 9.63 IL13 IL4
43 regulation of histamine secretion by mast cell GO:1903593 9.63 VAMP2 VAMP3
44 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IFNG IL10 IL4
45 positive regulation of T cell proliferation GO:0042102 9.55 CD40LG IFNG IL2 IL2RA IL4
46 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.43 SNAP25 STX3 VAMP2
47 immune response GO:0006955 9.36 CCR7 CD27 CD40LG IFNG IL10 IL13
48 positive regulation of T cell differentiation GO:0045582 9.26 CD27 IL2 IL2RA IL4
49 negative regulation of apoptotic process GO:0043066 10.1 CD27 CD40LG IL10 IL2 IL4
50 positive regulation of cell proliferation GO:0008284 10.1 IFNG IL2 IL4 IL5 STX3

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.67 IL10 IL2 IL4 IL5
2 syntaxin binding GO:0019905 9.62 NSF SNAP23 VAMP2 VAMP7
3 syntaxin-1 binding GO:0017075 9.56 NSF SNAP25 VAMP2 VAMP3
4 cytokine activity GO:0005125 9.56 CD40LG IFNG IL10 IL13 IL2 IL4
5 SNARE binding GO:0000149 9.55 NSF STX3 VAMP2 VAMP3 VAMP7
6 SNAP receptor activity GO:0005484 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7

Sources for Tetanus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....